A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085)

被引：0
|
作者：
Yu, E.
Massard, C.
Gross, M.
Wilding, G.
Posadas, E.
Culine, S.
Carducci, M. A.
Trudel, G.
Paliwal, P.
Sternberg, C.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Louis Warschaw Prostate Canc Ctr, Los Angeles, CA USA
[4] UWCCC, Madison, WI USA
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] CHU Henri Mondor, F-94010 Creteil, France
[7] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] San Camillo Forlanini Hosp, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5147
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
    Yu, Evan Y.
    Massard, Christophe
    Gross, Mitchell E.
    Carducci, Michael A.
    Culine, Stephane
    Hudes, Gary
    Posadas, Edwin M.
    Sternberg, Cora N.
    Wilding, George
    Trudel, Geralyn C.
    Paliwal, Prashni
    Fizazi, Karim
    UROLOGY, 2011, 77 (05) : 1166 - 1171
  • [2] Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
    Yu, Evan Y.
    Wilding, George
    Posadas, Edwin
    Gross, Mitchell
    Culine, Stephane
    Massard, Christophe
    Morris, Michael J.
    Hudes, Gary
    Calabro, Fabio
    Cheng, Shinta
    Trudel, Geralyn C.
    Paliwal, Prashni
    Sternberg, Cora N.
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7421 - 7428
  • [3] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [4] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
    Guadalupi, V.
    Giganti, M. O.
    Testa, I.
    Villa, S.
    Nicolai, N.
    Biasoni, D.
    Salvioni, R.
    Valdagni, R.
    Bajetta, E.
    Procopio, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
  • [5] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [6] Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180-086
    Araujo, J.
    Mathew, R.
    Armstrong, A. J.
    Braud, E. L.
    Posadas, E.
    Lonberg, M.
    Gallick, G.
    Trudel, G. C.
    Paliwal, P.
    Logothetis, C. J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 415 - 415
  • [7] Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
    Mahammedi, Hakim
    Pouget, Melanie
    Planchat, Eloise
    Cure, Herve
    Durando, Xavier
    Bayet-Robert, Mathilde
    Van-Praagh, Isabelle
    Atger, Marc
    Guy, Laurent
    Abrial, Catherine
    Chollet, Philippe J. M.
    Eymard, Jean-Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC).
    Spreafico, Anna
    Chi, Kim N.
    Sridhar, Srikala S.
    Smith, David C.
    Carducci, Michael Anthony
    Kavsak, Peter
    Wong, Tracy S.
    Wang, Lisa
    Ivy, S. Percy
    Mukherjee, Som Dave
    Kollmannsberger, Christian K.
    Hotte, Sebastien J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086)
    Araujo, J.
    Armstrong, A. J.
    Braud, E. L.
    Posadas, E.
    Lonberg, M.
    Gallick, G. E.
    Trudel, G. C.
    Paliwal, P.
    Agrawal, S.
    Logothetis, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)
    Leibrandt, Ryan
    Ullah, Ayman Teeham
    Verma, Rashmi
    Gao, Allen
    Lara, Primo N., Jr.
    Pan, Chong-xian
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345